This article is more than 5 years old. Information may no longer be current.

GrayBug raises $1.74 million in Series A2 financing

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

GrayBug has secured $1.74 million in Series A2 financing, according to a press release.

The financing round was led by a new investor, Hatteras Venture Partners, and an existing investor, Maryland Venture Fund.

The funds will support the development of GB-102, a proprietary microparticle candidate for wet age-related macular degeneration, the release said.

The company also announced that Christy Shaffer, PhD, managing director of Hatteras Discovery at Hatteras Venture Partners, was named chair of GrayBug’s board of directors.